Halis Sonmez, MD
Endocrinology, Diabetes & Metabolism · Rego Park, NYNPI 1578792834
Payments from drug & device makers
Across 202 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$672
- Amneal Pharmaceuticals LLC$664
- Amgen$631
- AbbVie$566
- Abbott$395
- Mannkind Corporation$379
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,67698%
- Education$421%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $672 |
| Amneal Pharmaceuticals LLC | 27 | $664 |
| Amgen | 22 | $631 |
| AbbVie | 26 | $566 |
| Abbott | 16 | $395 |
| Mannkind Corporation | 6 | $379 |
| Radius Health, Inc. | 14 | $245 |
| AstraZeneca | 8 | $160 |
| Xeris Pharmaceuticals, Inc. | 2 | $149 |
| Boehringer Ingelheim | 6 | $142 |
| Lilly USA, LLC | 7 | $128 |
| Ascendis Pharma Endocrinology Inc | 6 | $120 |
| Amarin Pharma, Inc. | 6 | $110 |
| Merck | 3 | $57 |
| Insulet Corporation | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Dynavax Technologies Corporation | 5 | $41 |
| Exact Sciences | 1 | $34 |
| Tandem Diabetes Care, Inc. | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| Ardelyx, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $16 |
| Micro-tech Endoscopy USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,778 in reported general payments places this provider in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 440 | $688,390 |
| OzempicSemaglutide | 329 | $540,336 |
| FarxigaDapagliflozin Propanediol | 236 | $256,524 |
| RybelsusSemaglutide | 146 | $229,514 |
| JardianceEmpagliflozin | 213 | $211,516 |
| TrulicityDulaglutide | 102 | $147,745 |
| TradjentaLinagliptin | 143 | $137,786 |
| VascepaIcosapent Ethyl | 190 | $107,824 |
| Metformin Er GastricMetformin Hcl | 65 | $88,990 |
| ProliaDenosumab | 49 | $78,780 |
| JanuviaSitagliptin Phosphate | 55 | $64,704 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 58 | $64,567 |
| Teriparatide | 26 | $42,890 |
| TymlosAbaloparatide | 16 | $42,762 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $41,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $128 | $836,135542 claims |
| Novo NordiskOzempic, Rybelsus | $672 | $769,850475 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $142 | $357,151369 claims |
| AstraZenecaFarxiga | $160 | $256,524236 claims |
| MerckJanuvia, Janumet Xr, Janumet | $57 | $151,349138 claims |
| AmgenProlia | $631 | $78,78049 claims |
| Radius Health, Inc.Tymlos | $245 | $42,76216 claims |
| AbbVieSynthroid | $566 | $37,859418 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $664 | $4,490335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Rego Park
- Maria PenaRego Park$239K
- Stella IlyayevaRego Park$219K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.